Preliminary results from the NM cohort of patients receiving abemaciclib, a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor, in breast cancer revealed a PFS of 5.9 months and an OS of 8.4 months [81]. The gene discussed is CDK4; the disease is breast carcinoma.